Recruiting

SIRA-1000

Sponsor:

Innoblative Designs, Inc.

Code:

NCT07206121

Conditions

Breast Cancer

Breast-conserving Surgery

Breast Cancer - Infiltrating Ductal Carcinoma

ER/PR+Her2neu

Grade I, II, III

Eligibility Criteria

Sex: Female

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Radiofrequency ablation alone

Radiofrequency ablation Electrosurgical Device

Study Details

Brief summary:

This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.

Conditions

Breast Cancer

Breast-conserving Surgery

Breast Cancer - Infiltrating Ductal Carcinoma

ER/PR+Her2neu

Grade I, II, III

Study ID

NCT07206121

Start date

Feb 10, 2026

Status verified date

Sep, 2025

Completion date

Feb 6, 2032

Anticipated

Primary completion date

Feb 6, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Biologic female
2. 50 years of age and older
3. Confirmed diagnosis of breast cancer:

1. Infiltrating ductal carcinoma
2. ER/PR+Her2neu-
3. Grade I, II, or III
4. Unicentric, unilateral tumor size ≤ 3cm
5. Tumor location ≥ 2 cm from skin and other structures
6. Zubrod Performance Status of 0, 1, or 2
7. No palpable lymphadenopathy
8. Able and willing to provide written informed consent

Exclusion Criteria:

1. Pregnant or breastfeeding
2. Neoadjuvant chemotherapy
3. Cardiac arrhythmia
4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device
5. Current or history of breast implants
6. Multi-centric or bilateral breast cancer
7. Diffuse microcalcifications
8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study
9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Feasibility and safety study for women undergoing BCS.

RFA electrosurgical device as an adjunct to BCS.

Interventions

Radiofrequency ablation alone

Demonstrate the accuracy of the device to produce approximately 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation tissue samples at least 1cm deep.

Radiofrequency ablation Electrosurgical Device

SIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.

Primary outcome measure

  • To assess the safety of SIRA-1000 by summarizing the occurrence of Adverse Events. [ Time Frame: The study will span a total of approximately 12 months with a follow-up for 5 years. ]
  • Healing Process assessed by BREAST-Q Questionnaire [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Clinical Trials Manager

833-920-4660kathy@innoblative.com

VP Quality Assurance & Regulatory Affairs

833-920-4660kcrowley@innoblative.com

Locations

University of Texas Medical Branch at Galveston, TX

Recruiting

Galveston, Texas, United States, 60612

Contacts

Sr. Clinical Research Coordinator

409-772-1983jearober@utmb.edu

Senior Research Coordinator

409-266-6388mmdimaan@utmb.edu

Principal Investigator:

Raj G. Vaghjiani, MD

More Information

Sponsor

Innoblative Designs, Inc.

Last update posted

Feb 11, 2026

Last verified

Sep, 2025

Keywords

  • Breast conserving surgery for breast cancer.

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Innoblative Designs, Inc. on 2026-02-11.